1. Home
  2. PRHIZ vs XGN Comparison

PRHIZ vs XGN Comparison

Compare PRHIZ & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRHIZ
  • XGN
  • Stock Information
  • Founded
  • PRHIZ N/A
  • XGN 2002
  • Country
  • PRHIZ United States
  • XGN United States
  • Employees
  • PRHIZ N/A
  • XGN N/A
  • Industry
  • PRHIZ Property-Casualty Insurers
  • XGN Medical Specialities
  • Sector
  • PRHIZ Finance
  • XGN Health Care
  • Exchange
  • PRHIZ Nasdaq
  • XGN Nasdaq
  • Market Cap
  • PRHIZ 220.0M
  • XGN 253.9M
  • IPO Year
  • PRHIZ N/A
  • XGN 2019
  • Fundamental
  • Price
  • PRHIZ $20.40
  • XGN $11.98
  • Analyst Decision
  • PRHIZ
  • XGN Strong Buy
  • Analyst Count
  • PRHIZ 0
  • XGN 6
  • Target Price
  • PRHIZ N/A
  • XGN $12.17
  • AVG Volume (30 Days)
  • PRHIZ N/A
  • XGN 279.7K
  • Earning Date
  • PRHIZ N/A
  • XGN 11-04-2025
  • Dividend Yield
  • PRHIZ N/A
  • XGN N/A
  • EPS Growth
  • PRHIZ N/A
  • XGN N/A
  • EPS
  • PRHIZ N/A
  • XGN N/A
  • Revenue
  • PRHIZ N/A
  • XGN $58,862,000.00
  • Revenue This Year
  • PRHIZ N/A
  • XGN $22.50
  • Revenue Next Year
  • PRHIZ N/A
  • XGN $14.19
  • P/E Ratio
  • PRHIZ N/A
  • XGN N/A
  • Revenue Growth
  • PRHIZ N/A
  • XGN 3.89
  • 52 Week Low
  • PRHIZ N/A
  • XGN $2.38
  • 52 Week High
  • PRHIZ N/A
  • XGN $12.01
  • Technical
  • Relative Strength Index (RSI)
  • PRHIZ N/A
  • XGN 70.61
  • Support Level
  • PRHIZ N/A
  • XGN $11.58
  • Resistance Level
  • PRHIZ N/A
  • XGN $11.85
  • Average True Range (ATR)
  • PRHIZ 0.00
  • XGN 0.33
  • MACD
  • PRHIZ 0.00
  • XGN 0.01
  • Stochastic Oscillator
  • PRHIZ 0.00
  • XGN 82.76

About XGN Exagen Inc.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Share on Social Networks: